

Gary Kohanbash

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4288762/publications.pdf>

Version: 2024-02-01

77
papers

4,275
citations

185998

28
h-index

189595

50
g-index

81
all docs

81
docs citations

81
times ranked

7411
citing authors

#	ARTICLE	IF	CITATIONS
1	Novel EGFRvIII-CAR transgenic mice for rigorous preclinical studies in syngeneic mice. <i>Neuro-Oncology</i> , 2022, 24, 259-272.	0.6	6
2	Loss of MAT2A compromises methionine metabolism and represents a vulnerability in H3K27M mutant glioma by modulating the epigenome. <i>Nature Cancer</i> , 2022, 3, 629-648.	5.7	16
3	Handheld PET Probe for Pediatric Cancer Surgery. <i>Cancers</i> , 2022, 14, 2221.	1.7	3
4	Quantitative Sodium (²³ Na) MRI in Pediatric Gliomas: Initial Experience. <i>Diagnostics</i> , 2022, 12, 1223.	1.3	2
5	Blocking NHE1 stimulates glioma tumor immunity by restoring OXPHOS function of myeloid cells. <i>Theranostics</i> , 2021, 11, 1295-1309.	4.6	24
6	Oncolytic HSV Vectors and Anti-Tumor Immunity. <i>Current Issues in Molecular Biology</i> , 2021, 41, 381-468.	1.0	8
7	TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma. <i>Frontiers in Immunology</i> , 2021, 12, 637146.	2.2	32
8	Chitinase-3-like 1 protein complexes modulate macrophage-mediated immune suppression in glioblastoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	49
9	Treatment of glioblastoma with current oHSV variants reveals differences in efficacy and immune cell recruitment. <i>Molecular Therapy - Oncolytics</i> , 2021, 22, 444-453.	2.0	1
10	Novel theranostic agent for PET imaging and targeted radiopharmaceutical therapy of tumour-infiltrating immune cells in glioma. <i>EBioMedicine</i> , 2021, 71, 103571.	2.7	13
11	Preclinical ImmunoPET Imaging of Glioblastoma-Infiltrating Myeloid Cells Using Zirconium-89 Labeled Anti-CD11b Antibody. <i>Molecular Imaging and Biology</i> , 2020, 22, 685-694.	1.3	32
12	Blockade of Cell Volume Regulatory Protein NKCC1 Increases TMZ-Induced Glioma Apoptosis and Reduces Astrogliosis. <i>Molecular Cancer Therapeutics</i> , 2020, 19, 1550-1561.	1.9	22
13	Abstract 6346: Optimizing precision combination therapies based on single-cell profiling of brain tumor biopsies. , 2020, , .		0
14	Abstract 4443: Inhibition of PGE2/EP4 pathway by ONO-4578/BMS-986310, a novel EP4 antagonist, promotes T cell activation and myeloid cell differentiation to dendritic cells. <i>Cancer Research</i> , 2020, 80, 4443-4443.	0.4	2
15	EPCO-32. AN EPIGENETIC SINGLE-CELL ATLAS OF IDH-MUTANT GLIOMA REVEALS THE ROLE OF ATRX IN SHAPING TUMOR COMPOSITION. <i>Neuro-Oncology</i> , 2020, 22, ii76-ii76.	0.6	0
16	EPCO-17. A SINGLE-CELL ATLAS OF GLIOBLASTOMA EVOLUTION UNDER THERAPY. <i>Neuro-Oncology</i> , 2020, 22, ii72-ii73.	0.6	0
17	Immunopeptidomics and Peptide Expression Profiles to Develop T-Cell Receptors Against Glioma-Associated Antigens. <i>Neurosurgery</i> , 2019, 66, .	0.6	0
18	The Phenotypes of Proliferating Glioblastoma Cells Reside on a Single Axis of Variation. <i>Cancer Discovery</i> , 2019, 9, 1708-1719.	7.7	205

#	ARTICLE	IF	CITATIONS
19	Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. <i>Cancer Research</i> , 2019, 79, 4026-4041.	0.4	16
20	DIPG-11. ACTIVATION OF RAS SIGNALING AND DISTINCT MITOGEN-ACTIVATED PROTEIN KINASES (MAPKs) PROVIDES UNIQUE THERAPEUTIC VULNERABILITIES IN MUTANT HISTONE DIPG. <i>Neuro-Oncology</i> , 2019, 21, ii70-ii70.	0.6	0
21	IMMU-16. GUADECITABINE (SGI-110) IMMUNOSENSITIZES MURINE C57BL/6-SYNGENEIC GLIOMA AND DIPG MODELS. <i>Neuro-Oncology</i> , 2019, 21, ii96-ii96.	0.6	0
22	TMIC-19. H ⁺ EXTRUSION PROTEIN NA/H EXCHANGER IN METABOLIC POLARIZATION OF GLIOMA-ASSOCIATED MICROGLIA/MACROPHAGES AND TUMOR IMMUNITY. <i>Neuro-Oncology</i> , 2019, 21, vi251-vi251.	0.6	0
23	TMIC-39. DEVELOPMENT OF CD11b TRACER FOR THE IMMUNE PET IMAGING IN GLIOBLASTOMA MODEL - COULD BE A GAME CHANGER FOR IMMUNOTHERAPY APPROACHES. <i>Neuro-Oncology</i> , 2019, 21, vi256-vi256.	0.6	0
24	CSIG-01. NA-K-CL COTRANSPORTER PROTEIN IN THE PATHOGENESIS OF LOW-GRADE GLIOMAS. <i>Neuro-Oncology</i> , 2019, 21, vi44-vi44.	0.6	0
25	Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. <i>Journal of Experimental Medicine</i> , 2018, 215, 141-157.	4.2	186
26	TMIC-14. AUTO-/PARACRINE SIGNALING OF PI3K/AKT/YKL-40 IN MESENCHYMAL GLIOBLASTOMA PROGRESSION. <i>Neuro-Oncology</i> , 2018, 20, vi258-vi259.	0.6	0
27	IMMU-18. TARGETING THE PD1 AND TIGIT CHECKPOINT PATHWAYS FOR ADULT AND PEDIATRIC GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi125-vi125.	0.6	0
28	TMIC-34. Na/H EXCHANGER ISOFORM 1 (NHE1) IN IMMUNOSUPPRESSIVE TUMOR MICROENVIRONMENT IN MOUSE SYNGENEIC GLIOMA MODEL. <i>Neuro-Oncology</i> , 2018, 20, vi263-vi263.	0.6	0
29	IMMU-16. GUADECITABINE (SGI-110) ENHANCES MHC class I AND TUMOR ANTIGEN EXPRESSION ON MURINE C57BL/6-SYNGENEIC GLIOMA AND DIPG MODELS. <i>Neuro-Oncology</i> , 2018, 20, vi124-vi124.	0.6	0
30	IMMU-17. PEPTIDE VACCINE IMMUNOTHERAPY BIOMARKERS AND RESPONSE PATTERNS IN PEDIATRIC GLIOMAS. <i>Neuro-Oncology</i> , 2018, 20, vi124-vi125.	0.6	0
31	Blockade of Na/H exchanger stimulates glioma tumor immunogenicity and enhances combinatorial TMZ and anti-PD-1 therapy. <i>Cell Death and Disease</i> , 2018, 9, 1010.	2.7	47
32	Elevated Na/H exchanger 1 (SLC9A1) emerges as a marker for tumorigenesis and prognosis in gliomas. <i>Journal of Experimental and Clinical Cancer Research</i> , 2018, 37, 255.	3.5	45
33	Peptide vaccine immunotherapy biomarkers and response patterns in pediatric gliomas. <i>JCI Insight</i> , 2018, 3, .	2.3	21
34	Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy. <i>Oncogene</i> , 2017, 36, 3749-3759.	2.6	104
35	Single-cell profiling of human gliomas reveals macrophage ontogeny as a basis for regional differences in macrophage activation in the tumor microenvironment. <i>Genome Biology</i> , 2017, 18, 234.	3.8	448
36	IMMU-41. H3.3K27M MUTATION-DERIVED NOVEL NEOANTIGEN " CHARACTERIZATION OF THE HLA-A2-BINDING EPITOPE AND A-SPECIFIC T CELL RECEPTOR FOR DEVELOPMENT OF T CELL-BASED IMMUNOTHERAPY. <i>Neuro-Oncology</i> , 2017, 19, vi121-vi121.	0.6	0

#	ARTICLE	IF	CITATIONS
37	IMMU-52. SELECTION OF GLIOMA T-CELL THERAPY TARGETS BASED ON THE ANALYSIS OF TUMOR IMMUNOPEPTIDOME AND EXPRESSION PROFILES. <i>Neuro-Oncology</i> , 2017, 19, vi124-vi124.	0.6	0
38	IMMU-42. ONO-AE3-208 PROMOTES ANTI-TUMOR IMMUNE ACTIVITY AND SURVIVAL IN GLIOMA MODELS. <i>Neuro-Oncology</i> , 2017, 19, vi122-vi122.	0.6	0
39	Isoictrate dehydrogenase mutations suppress STAT1 and CD8+ T cell accumulation in gliomas. <i>Journal of Clinical Investigation</i> , 2017, 127, 1425-1437.	3.9	334
40	TMIC-11. TUMOR GENETICS AND MACROPHAGE ONTOGENY SHAPE THE INNATE IMMUNE RESPONSE TO GLIOMA. <i>Neuro-Oncology</i> , 2017, 19, vi245-vi245.	0.6	0
41	HG-81 NOVEL AND SHARED NEOANTIGEN FOR GLIOMA T CELL THERAPY DERIVED FROM HISTONE 3 VARIANT H3.3 K27M MUTATION. <i>Neuro-Oncology</i> , 2016, 18, iii67.1-iii67.	0.6	1
42	IMST-09. IDENTIFICATION OF A NOVEL H3.3.K27M MUTATION-DERIVED NEOANTIGEN EPITOPE AND CLONING OF A SPECIFIC T-CELL RECEPTOR FOR T-CELL THERAPY IN GLIOMAS. <i>Neuro-Oncology</i> , 2016, 18, vi87-vi87.	0.6	0
43	IMST-14. IDH1 R132H MUTATION INHIBITS ANTI-GLIOMA IMMUNE RESPONSES THROUGH POST-TRANSCRIPTIONAL DOWN-REGULATION OF STAT1 AND TYPE-1 CHEMOKINES. <i>Neuro-Oncology</i> , 2016, 18, vi88-vi88.	0.6	0
44	Single-cell sequencing maps gene expression to mutational phylogenies in PDGF- and EGF-driven gliomas. <i>Molecular Systems Biology</i> , 2016, 12, 889.	3.2	91
45	IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression. <i>Neuro-Oncology</i> , 2016, 18, 1402-1412.	0.6	126
46	Detection of inflammatory cell function using ¹³ C magnetic resonance spectroscopy of hyperpolarized [6- ¹³ C]-arginine. <i>Scientific Reports</i> , 2016, 6, 31397.	1.6	24
47	Safety Study: Intraventricular Injection of a Modified Oncolytic Measles Virus into Measles-Immune, hCD46-Transgenic, IFN- β Rko Mice. <i>Human Gene Therapy Clinical Development</i> , 2016, 27, 145-151.	3.2	9
48	Expression and prognostic impact of immune modulatory molecule PD-L1 in meningioma. <i>Journal of Neuro-Oncology</i> , 2016, 130, 543-552.	1.4	90
49	IMST-04. IMAGING INFLAMMATORY CELL FUNCTION USING ¹³ C MAGNETIC RESONANCE SPECTROSCOPY OF HYPERPOLARIZED 6- ¹³ C-LABELED ARGININE. <i>Neuro-Oncology</i> , 2016, 18, vi86-vi86.	0.6	0
50	Prioritization schema for immunotherapy clinical trials in glioblastoma. <i>Oncolimmunology</i> , 2016, 5, e1145332.	2.1	13
51	IMPS-11 EXPRESSION AND PROGNOSTIC IMPACT OF IMMUNE MODULATORY MOLECULE PD-L1 IN MENINGIOMA. <i>Neuro-Oncology</i> , 2015, 17, v115.2-v115.	0.6	0
52	MTR-01 BEVACIZUMAB-INDUCED MIF DEPLETION: A NOVEL RESISTANCE MECHANISM IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2015, 17, v124.1-v124.	0.6	8
53	GENO-14 SINGLE-CELL TRANSCRIPTOMICS AND GENOMICS REVEALS A DIVERSITY OF TUMOR AND IMMUNE CELL POLARIZATION SIGNALS IN GBM. <i>Neuro-Oncology</i> , 2015, 17, v94.2-v94.	0.6	0
54	Transgene-derived overexpression of miR-17-92 in CD8+ T-cells confers enhanced cytotoxic activity. <i>Biochemical and Biophysical Research Communications</i> , 2015, 458, 549-554.	1.0	26

#	ARTICLE	IF	CITATIONS
55	Induction of Robust Type-1 CD8+ T-cell Responses in WHO Grade 2 Low-Grade Glioma Patients Receiving Peptide-Based Vaccines in Combination with Poly-ICLC. <i>Clinical Cancer Research</i> , 2015, 21, 286-294.	3.2	92
56	Histamine deficiency promotes accumulation of immunosuppressive immature myeloid cells and growth of murine gliomas. <i>Oncolimmunology</i> , 2015, 4, e1047581.	2.1	12
57	Abstract 4846: Histamine in myeloid cell maturation and malignant glioma development. , 2014, , .		0
58	GM-CSF Promotes the Immunosuppressive Activity of Glioma-Infiltrating Myeloid Cells through Interleukin-4 Receptor- β . <i>Cancer Research</i> , 2013, 73, 6413-6423.	0.4	169
59	Premetastatic soil and prevention of breast cancer brain metastasis. <i>Neuro-Oncology</i> , 2013, 15, 891-903.	0.6	76
60	Differential activity of interferon- β promoter is regulated by Oct-1 and a SNP that dictates prognosis of glioma. <i>Oncolimmunology</i> , 2012, 1, 487-492.	2.1	11
61	Myeloid-derived Suppressor Cells (MDSCs) in Gliomas and Glioma-Development. <i>Immunological Investigations</i> , 2012, 41, 658-679.	1.0	56
62	MicroRNAs and STAT interplay. <i>Seminars in Cancer Biology</i> , 2012, 22, 70-75.	4.3	94
63	Abstract 1246: ELK-1 regulates interferon-alpha8 expression via a polymorphic region in the interferon-alpha8 promoter associated with outcome of glioma patients. , 2012, , .		0
64	COX-2 Blockade Suppresses Gliomagenesis by Inhibiting Myeloid-Derived Suppressor Cells. <i>Cancer Research</i> , 2011, 71, 2664-2674.	0.4	331
65	Induction of CD8 ⁺ T-Cell Responses Against Novel Glioma-Associated Antigen Peptides and Clinical Activity by Vaccinations With β -Type 1 Polarized Dendritic Cells and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Patients With Recurrent Malignant Glioma. <i>Journal of Clinical Oncology</i> , 2011, 29, 330-336.	0.8	519
66	Poly-ICLC promotes the infiltration of effector T cells into intracranial gliomas via induction of CXCL10 in IFN- β and IFN- γ dependent manners. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 1401-1409.	2.0	83
67	Role of Type 1 IFNs in Antiglioma Immunosurveillance-Using Mouse Studies to Guide Examination of Novel Prognostic Markers in Humans. <i>Clinical Cancer Research</i> , 2010, 16, 3409-3419.	3.2	80
68	miR-17-92 expression in differentiated T cells - implications for cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2010, 8, 17.	1.8	67
69	MicroRNAs in immune regulation-Opportunities for cancer immunotherapy. <i>International Journal of Biochemistry and Cell Biology</i> , 2010, 42, 1256-1261.	1.2	78
70	Abstract 4786: MiR-17-92 expression in differentiated T cells - Implications for cancer immunotherapy. , 2010, , .		1
71	Abstract 1359: COX2 blockade suppresses glioma-genesis by promoting anti-glioma immunosurveillance. , 2010, , .		0
72	Effective Immunotherapy against Murine Gliomas Using Type 1 Polarizing Dendritic Cells-Significant Roles of CXCL10. <i>Cancer Research</i> , 2009, 69, 1587-1595.	0.4	99

#	ARTICLE	IF	CITATIONS
73	Systemic Inhibition of Transforming Growth Factor- β 2 in Glioma-Bearing Mice Improves the Therapeutic Efficacy of Glioma-Associated Antigen Peptide Vaccines. <i>Clinical Cancer Research</i> , 2009, 15, 6551-6559.	3.2	106
74	Dicer-regulated microRNAs 222 and 339 promote resistance of cancer cells to cytotoxic T-lymphocytes by down-regulation of ICAM-1. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2009, 106, 10746-10751.	3.3	161
75	IL-4 Suppresses Very Late Antigen-4 Expression Which is Required for Therapeutic Th1 T-cell Trafficking Into Tumors. <i>Journal of Immunotherapy</i> , 2009, 32, 793-802.	1.2	25
76	Immunotherapeutic Approaches for Glioma. <i>Critical Reviews in Immunology</i> , 2009, 29, 1-42.	1.0	132
77	Expression of glioma-associated antigens in pediatric brain stem and non-brain stem gliomas. <i>Journal of Neuro-Oncology</i> , 2008, 88, 245-250.	1.4	77